InVivo Therapeutics Names Sean Moran as Chief Financial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Corporation announced today that Sean Moran has joined InVivo’s management team as Chief Financial Officer. In this newly created position, Moran will play a key leadership role as the company continues to drive the development and commercialization of its novel biopolymer scaffolding device for the treatment of spinal cord injury.

Moran brings to InVivo more than twenty-six years of experience in financial management and sixteen years as a CFO for public and private companies. He has a deep background in life sciences and has served in senior financial roles for medical device, biotech and drug development companies. Moran has successfully raised capital and has extensive experience in corporate finance, mergers and acquisitions, investor and Wall Street relations and SEC reporting.

“InVivo has recruited world renowned scientists to our team and now the addition of Sean Moran to the company represents the beginning of building out of the business side of InVivo’s management team,” said Frank Reynolds, InVivo Therapeutics CEO. “In just a short time with InVivo, Sean has already shaped our financial strategies and we look forward to his continued contributions.”

“I am thrilled to have joined InVivo,” stated Moran. “The company’s technology has tremendous potential to help treat patients with devastating spinal cord injuries. InVivo’s product is moving into human clinical trials and the company is poised for explosive growth.”

Before joining InVivo, Moran served as Chief Financial Officer of four publicly traded companies, most recently at Celsion Corporation, as well as at Sontra Medical, SatCon Technology Corporation, and Anika Therapeutics. Moran was also the co-founder of Anika Therapeutics, and helped to take the company public through an IPO and guided it to profitability. Mr. Moran is a CPA and earned his M.B.A. and a B.S. in Accounting from Babson College.

InVivo Therapeutics Corporation, based in Cambridge, MA, is a leading medical device company focused on utilizing biopolymers as a platform technology to develop treatments to restore function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of research initiated in the laboratories of Robert Langer, PhD, of the Massachusetts Institute of Technology, Jay Vacanti, MD, of the Massachusetts General and Children’s Hospitals in Boston, and Yang Teng, PhD, MD, of Harvard's Brigham and Women's Hospital.



CONTACT:

InVivo Therapeutics Corporation
Frank Reynolds, 617-475-1517
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Medical Devices  Pharmaceutical  Other Health  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.